M o l # 9 1 5 9 5 7 al., 2000; Tadokoro et al., 2011 ). There is a major difference in the mechanisms of cellular trafficking and recycling of PAR1 and PAR4, wherein activated PAR1 gets phosphorylated at serine residues in its cytoplasmic tail and is rapidly internalized independent of arrestins (Hoxie et al., 1993; Trejo and Coughlin, 1999) ; in contrast, PAR4 is not phosphorylated and internalized rather slowly (Kahn et al., 1999; Shapiro et al., 2000) . We have previously shown that inhibition of P2Y12 reduces PAR4-mediated Akt activation and recruitment of arrestin-2 to PAR4 signaling complexes. We further showed that PAR4 and P2Y12 co-immunoprecipitate upon PAR4 activation in human platelets (Li et al., 2008; Li et al., 2011) . In this report, we investigate the possibility that direct association of P2Y12 and PAR4 mediates arrestin recruitment to PAR4 and contributes to the consequent Akt activation.
Dimer-or oligomerization of GPCRs has increasingly been reported in platelets (de la Fuente et al., 2012; Frey et al., 2013; Leger et al., 2006; Savi et al., 2006) and other cell types (Angers et al., 2002; Rozenfeld and Devi, 2011) . Structure/function studies of GPCR oligomerization have demonstrated that the transmembrane helices (TM), most commonly TM4-6 of GPCRs, provide the interfaces for dimerization of many GPCRs (Filizola and Weinstein, 2005) . Homo-or heterotypic interaction of GPCRs affects their pharmacological properties, interactions with scaffolding molecules, and downstream signaling events. For example, it has previously been shown that paired activation of both components of M3 receptor dimers is required for beta-arrestin recruitment to the receptor ( (Novi et al., 2005) . More recently, PAR1-PAR2 heterodimers were shown to elicit arrestin-dependent signaling to endosomes (Lin and Trejo, 2013) . With these models in mind, we expressed fluorescent and luciferase-tagged forms of PAR4 and M o l # 9 1 5 9 5 8 P2Y12 in a heterologous expression system to determine whether the receptors directly interact using Bioluminescent Resonance Energy Transfer (BRET) and to determine whether signaling responses in the cells were dependent upon their direct interaction.
We demonstrate that PAR4 and P2Y12 specifically and directly interact, whereas PAR1
and P2Y12 do not. PAR1 and PAR4 show specific sequence divergence at the base of TM4. Interestingly, TM4 of PAR4 has been reported to be necessary for its homodimerization (de la Fuente et al., 2012) and could potentially regulate heterodimer formation with other receptors. Hence, using a site-directed mutagenic approach, we designed a mutant variant of PAR4 (PAR4SFT) containing a 3-amino acid substitution at the base of TM4 (based upon PAR1 sequence at this location). We show that PAR4SFT does not interact with P2Y12 and fails to support P2Y12-dependent arrestin recruitment and Akt activation. Interestingly, PAR4SFT also fails to support Gqmediated calcium mobilization when expressed on its own, but this response could be rescued by its dimerization with (wildtype) PAR4. We conclude that the agonistdependent specific interaction of PAR4 with P2Y12 supports sustained signaling to Akt that is partially dependent on recruitment of arrestin-2 to PAR4, and this mechanism is likely important for the PAR4 and P2Y12-dependent stabilization of platelet thrombi. Immunoblotting: HEK293T cells stably expressing PAR4 and P2Y12 (2 x 10 6 cells/ml) were grown to 70% confluency, and starved for 12 hours. They were then treated with agonist for 10 minutes at 37°C or antagonist for 10 minutes at room temperature; lysed in 1X lysis buffer (1% triton-100, 150 mM NaCl, 10 mM Tris, 0.5% deoxycholic acid, 5 mM EDTA, 0.5 mM PMSF, pH 7.4) with freshly added 1% Triton, 1X protease inhibitor and rotated at 4°C overnight followed by proteinA/G agarose 15μl/ml at 4°C for 2 hours.
Samples were washed with 1x IP buffer 3 times and applied in Laemmli buffer to 10% SDS-PAGE for immunoblotting.
Calcium mobilization assay: HEK293T cells were transiently transfected and/or cotranfected with V5-PAR4-GFP and HA-PAR4SFT-GFP. Co-transfections were done as PAR4:PAR4SFT in increasing ratios 1:1 and 1:2, where 0.1μg of PAR4 was used since it gave the smallest detectable calcium flux. 48hr post-transfection cells were removed Platelet isolation and preparation of Human blood: Blood for biochemical studies of human platelets was collected by venipuncture from adult human volunteers after
providing written informed consent as approved by the Institutional Review Board at University of Delaware. Blood was collected into a 60-cc syringe containing ACD (trisodium citrate, 65mM; citric acid, 70mM; dextrose, 100mM; pH 4.4) at a ratio of 1:6 parts ACD/blood. Anticoagulated blood was spun by centrifugation at 250xg and the supernatant containing platelet rich plasma (PRP) was then pelleted at 750xg (10 minutes), washed once in HEN buffer (10mM HEPES, pH 6.5, 1mM EDTA, 150mM
NaCl) containing 0.05 U/ml apyrase and platelets resuspended with HEPES-Tyrode's buffer (137mM NaCl, 20mM HEPES, 5.6mM glucose, 1 g/l BSA, 1mM MgCl2, 2.7mM
KCl, 3.3mM NaH2PO4) at a concentration of from 4x10 8 platelets/ml in HEPESTyrode's buffer containing 0.05 U/ml apyrase, for immunoblotting, immunoprecipitation.
Statistical analyses: Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). For pairwise comparisons, unpaired t-tests were performed. For comparisons across three groups or larger one-way ANOVA, followed by post hoc tests (Tukey Kramer) were performed. p values= * <0.05, ** <0.01, ***<0.001, were considered significant. Data are shown as means ± S.E.M. The direct interaction between P2Y12 and PAR4 was assessed using BRET. Briefly,
BRET is a measurement of the energy transfer from the donor enzyme (Rluc) which oxidizes its substrate: coelenterazine to coelenteramide, which in turn results in a nonradiative emission at 485nm. When EYFP, the acceptor fluorophore is within 10 nanometers of the Rluc, emission from the coelenteramide at 485 nm in turn excites the EYFP on the neighboring acceptor molecule (Gandia et al., 2008) and results in emission at a peak of 527 nm. The interaction between Rluc-P2Y12 and PAR4-YFP is specific and saturable, as no BRET was detected due to co-expression of Rluc-P2Y12
with either vector expressing YFP alone ( (Fig. 1B) . Basal interaction of PAR4 with P2Y12 is probably due to their constitutive activity, since increased constitutive activity of diverse GPCRs has been demonstrated by measuring secondary messenger activities following expression in heterologous systems (Daeffler and Landry, 2000; Milligan et al., 1995; Tiberi and Caron, 1994) . A significant increase in net BRET signal following PAR4 activation and decrease in the presence of P2Y12 antagonist suggests that association of PAR4 with P2Y12 is driven by the active states of both receptors.
P2Y12 directly associates with PAR4, but not PAR1
To determine whether the agonist-dependent association of P2Y12 with PAR4 is specific, we compared the interaction of P2Y12 with PAR4 and its ability to associate with PAR1.
Comparative saturation BRET assays demonstrate that the BRET50 for PAR4-P2Y12 interaction is 3.1± 0.4; however, PAR1-YFP did not demonstrate any
residues at the aligned position (SFT 220-222). We found that PAR4SFT fails to interact with P2Y12 when assessed by saturation BRET (Fig. 3A) . Notably, residues in the 4 th transmembrane domain have also been demonstrated to promote PAR4 homodimer formation (de la Fuente et al., 2012) . To determine whether residues
LGL (194) (195) (196) at the base of TM4 also contribute to PAR4 homodimerization, we tested whether PAR4SFT could homodimerize with (wildtype) PAR4 when the two receptors were co-expressed in HEK293T cells and assessed using saturation BRET (Fig 3B) .
The results show that luciferase-tagged PAR4 interacted equally well with PAR4SFT-YFP as with PAR4-YFP, indicating that these residues specifically support association with P2Y12, but are not required for the homodimeric interaction.
When expressed in HEK293T cells, co-immunoprecipitation of PAR4 or PAR4SFT with P2Y12 also supports this finding (Fig 3A) , with an observed increase in PAR4-P2Y12 receptor co-immunoprecipitation upon agonist treatment and a comparatively less coimmunoprecipitation of P2Y12 with PAR4SFT relative to PAR4 (Fig. 4A ). All the receptors P2Y12, PAR4 and PAR4SFT were expressed on the HEK293T cell membranes; hence the reduction in co-immunoprecipitation of PAR4SFT and P2Y12
was not due to abnormal receptor trafficking to the membrane (Fig. 4B, C) . To determine if endogenous ADP levels in the media could promote the basal PAR4-P2Y12 association observed, co-immunoprecipitation studies were conducted in the presence and absence of apyrase. Figure 4D shows that, apyrase treatment does not alter the basal level of PAR4 and P2Y12 association. 5 ). We observed that PAR4 co-immunoprecipitates with arrestin-2 upon activation, and only in presence of P2Y12 expression (Fig. 5A, C) . When PAR4SFT was co-expressed with P2Y12, it failed to associate with arrestin even after PAR4 activation (Fig. 5B ).
However P2Y12 can associate with arrestin by itself upon ADP stimulation (Fig 5D) suggesting that PAR4-P2Y12 dimerization assists arrestin recruitment to PAR4 with P2Y12 as a mediator.
Using the previously-described stable cell lines, we next tested whether PAR4-P2Y12 interaction was required for Akt activation. Stimulation with PAR4-AP peptide resulted in substantial Akt activation in PAR4 and P2Y12 co-expressing 293T cells; however,
PAR4-AP failed to cause Akt activation in cells co-expressing PAR4SFT and P2Y12, implying that the failure to dimerize with P2Y12 abolishes the ability of PAR4 to associate with arrestin and influences downstream Akt activation (Fig. 6) . When expressed alone, P2Y12 however can activate Akt upon ADP stimulation (Fig 6C) .
PAR4SFT fails to induce calcium mobilization independently but potentiates PAR4 mediated calcium flux:
Finally, Gq-coupled calcium mobilization responses of PAR4 and PAR4SFT were assessed by evaluating the relative fluorescence of PAR4-stimulated, Fluo4-AM-loaded HEK293T cells transiently expressing PAR4 or PAR4SFT. When expressed individually, PAR4SFT failed to induce a calcium flux upon stimulation with increasing AYPGKF concentration (from 1-8mM) even though PAR4 and PAR4SFT were expressed with equal efficiency (Fig. 7A, B) , implying that it is unable to activate Gq by itself. PAR4 homodimerization has been reported to be essential for calcium mobilization (de la Fuente et al., 2012), hence we reasoned that the defect in calcium mobilization seen with PAR4SFT could be due to the inability of the mutant to form homodimers. Importantly, however, we have shown that PAR4SFT can dimerize with wild type PAR4 (Fig. 3B) . Therefore, we hypothesized that dimeric PAR4 is required for functional Gq coupling. Hence we tested whether increased expression of PAR4SFT with (wildtype) PAR4 might alter the minimal amount of PAR4 required to generate a calcium response. When minimal amounts of PAR4 (0.1μg) (enough to see minimal detectable calcium flux) was co-transfected with increasing amounts of PAR4SFT (PAR4:PAR4SFT 1:1 and 1:2), a PAR4SFT receptor dose-dependent increase in calcium response was detected (Fig. 7C, D) , suggesting that PAR4SFT can dimerize with PAR4 to generate a functional dimer. This, together with our BRET data (Fig. 3B) shows that PAR4SFT can dimerize with PAR4, but not with itself to induce Gq-mediated responses.
PAR4 induced calcium mobilization influences PAR4 P2Y12 dimerization:
Given that PAR4SFT fails to elicit normal calcium responses when expressed in isolation, we reasoned that the inability of PAR4SFT to dimerize with P2Y12 could be secondary to its defect in eliciting Gq-coupled calcium responses. Hence, we evaluated whether calcium mobilization is required for association of PAR4 with P2Y12 in human platelets and HEK293T cells. Washed human platelets or HEK293T cells co-expressing PAR4 and P2Y12, were treated with calcium chelator, BAPTA-AM 10μM, and then stimulated with AYPGKF 150μM, followed by co-immunoprecipitation of PAR4 and P2Y12. Figure 8A and supplemental figure 2 show that in human platelets and HEK293T cells respectively, PAR4 stimulation promotes PAR4-P2Y12 association and can be blocked by BAPTA-AM. Thus, calcium mobilization is important in promoting receptor-receptor interaction, suggesting at least one mechanism by which receptor activation is required for PAR4-P2Y12 association. Consistent with our previous report, we also demonstrate in human platelets that PAR4-stimulated PAR4-P2Y12 association is prevented by inhibition of P2Y12 (Fig. 8B ). 
Discussion
An increasing number of studies have shown that GPCRs can exist as homo-or heterodimers, or higher order oligomers (Milligan, 2008; Milligan et al., 2004; Minneman, 2007; Smith and Milligan, 2010 In this study, we demonstrate using saturation BRET in HEK293T cells that the thrombin receptor PAR4 interacts directly with P2Y12 upon agonist activation.
Although some interaction is detected in the absence of agonist, this is likely caused by overexpression in the heterologous expression system which can elicit increased constitutive activity (Daeffler and Landry, 2000) . An increased net BRET output after PAR4 stimulation and a reduction in BRET in the presence of P2Y12 antagonist (Fig. 1) suggests that exposure of platelets in vivo to the physiological release of thrombin during thrombus formation could promote PAR4-P2Y12 heterodimerization and that P2Y12 or PAR4 inhibitors would block this event. Many GPCRs expressed in platelets have been reported to form homo-dimers or -oligomers independent of ligand activation, including PAR4, TP receptor, and P2Y12. Agonist-dependent regulation of PAR4-P2Y12 association in platelets suggests that these heterophilic associations might occur in a regulated, reversible fashion to promote sustained signaling events supporting longer-term thrombus stability.
Association of P2Y12 with PAR4 is specific, since P2Y12 does not interact with PAR1
when assessed by saturation or competition BRET (Fig. 2) . Structural motifs governing
GPCR interaction have been mapped to the TMs in many receptors (Complement factor
A receptor, Chemokine receptors, Dopamine and Beta adrenergic receptors) (Floyd et al., 2003; Klco et al., 2003) . Using the sequence divergence of PAR1 from PAR4 in the TM helices as a basis for site-directed mutagenesis, we identified a site at the base of the 4 th TM helix of PAR4 that disrupts the association between PAR4 and P2Y12, as well as Gq-coupled calcium mobilization. The impairment in PAR4-P2Y12 association could be a consequence of the defect in Gq signaling, implying that PAR4-dependent
calcium mobilization is required to promote PAR4 and P2Y12 dimerization. This further supports the idea that PAR4 activation is necessary for PAR4-P2Y12 dimerization.
Interestingly, the leucine zipper of PAR4 TM4 has been reported to be required for PAR4 homodimerization and intracellular calcium mobilization (de la Fuente et al., 2012) . Of note, the association of PAR4SFT with wildtype PAR4 is maintained in spite of the mutation (Fig. 3B ). This region is near the cytoplasmic interface, but C-terminal to the residues that have previously been shown to be required for PAR4
homodimerization, suggesting that discrete regions of TM4 govern association of PAR4
with another PAR4 protomer versus with P2Y12.
Given the reported existence of constitutive PAR4-PAR1 heterodimers (Leger et al., 2006) in platelets, the inability of PAR1 to compete with the interaction of PAR4 and P2Y12 raises at least two possible interpretations: 1) PAR4 interacts with P2Y12 at a site different from its interaction with PAR1. This possibility is likely, given that the two discrete mutations in TM4 show differential effect on the interaction of PAR4 with itself versus P2Y12 or 2) the affinity of PAR4 for P2Y12 in this HEK293T system is greater than that of PAR4 for PAR1. This may be the case in platelets only when PAR4 and P2Y12 are agonist-activated, since the PAR1-PAR4 interaction is constitutive in platelets, but the PAR4-P2Y12 is not. Although each of these complexes has been detected in platelets by co-immunoprecipitation, the relative amounts of PAR4 in each of these GPCR complexes remains to be quantified, as does whether these different complexes of PAR4 exist in different membrane domains, such as lipid rafts.
Given that receptor activation drives PAR4-P2Y12 association, and these receptors have been shown to play a role in thrombus stability in vivo, we wondered whether arrestin-dependent signaling responses as heterodimers that are not detected upon expression of the monomers alone (Rozenfeld and Devi, 2007; Rozenfeld and Devi, 2010; Small et al., 2006) . Arrestins serve as scaffolding molecules to signal through complexes that include clathrin, adaptin, mdm2, and, of particular relevance to our study, src family kinases (SFK), and PI3K (Gurevich and Gurevich, 2003; Lodeiro et al., 2009; Yang et al., 2009 ). We previously demonstrated that in mouse and human platelets, PAR4-AP induces a signaling complex of arrestin-2 , the p85 subunit of PI3K and the SFK, Lyn, which contributes to Akt activation in a P2Y12 dependent manner (Li et al., 2011) . Here, we show that PAR4 supports arrestin recruitment and arrestindependent Akt phosphorylation only in the presence of P2Y12 in HEK293T cells ( Fig. 5 and 6). In contrast, when PAR4SFT and P2Y12 are co-expressed, arrestin recruitment to AYPGKF-activated PAR4SFT is abolished, and Akt phosphorylation is inhibited.
Although many studies have reported that PAR4 signaling to Akt is P2Y12-dependent (Kim et al., 2006; Li et al., 2008) , a recent study demonstrated that PAR4 can independently activate Akt in P2Y12 knock-out mice and in COS-7 cells at high agonist concentration (AYPGKF 500μM-1000μM (Xiang et al., 2010 ). In the current study, coexpression of P2Y12 and PAR4 was required to detect PAR4-dependent Akt phosphorylation. Also our previous study demonstrated that arrestin-2 deletion reduced but did not ablate PAR4-dependent Akt phosphorylation. Taken together, these studies Additionally P2Y12 has been reported to bind arrestin-2 and undergo rapid internalization, suggesting a model whereby the direct interaction of P2Y12 with arrestin allows PAR4 to recruit arrestin together with P2Y12 upon PAR4-AP activation (Mundell et al., 2006) .
Curiously, mutation of TM4 LGL to residues SFT also disrupted PAR4-dependent calcium responses. This was a surprise, considering that PAR1, like PAR4, also couples to Gq. Nevertheless, it raises the question of whether this site is required both for PAR4-P2Y12 interaction and G protein association independently, or whether mutation of PAR4 affects G protein interaction which in turn influences PAR4-P2Y12
interaction. Interestingly, expressing increasing concentrations of PAR4SFT with coexpressed PAR4 potentiated calcium responses compared to expression of PAR4
alone. This implies that one protomer of PAR4 containing an intact TM4 is sufficient to interact with a PAR4SFT protomer. It also is consistent with a model in which PAR4
exists in a stoichiometric ratio of 2 GPCRs: 1 G protein, which has been the model suggested by previous reports of rhodopsin and leukotriene receptors (Jastrzebska et al., 2013; Liang et al., 2003; Maurice et al., 2011) .
In summary, we have shown that agonist-activated PAR4 recruits P2Y12-associated arrestin to PAR4 through direct association with P2Y12. We have previously shown that arrestin-dependent pathways contribute to Akt activation in platelets which in turn is important for the growth and stability of platelet-rich thrombi in vivo (Li et al., 2011; Woulfe, 2010) . Taken together, these studies suggest that the agonist-regulated
association of PAR4 with P2Y12 has functional consequences in promoting the stability of platelet thrombi. While GPCR heterodimerization has been demonstrated in a variety of cell systems, including platelets, their functional relevance in platelets is just beginning to be elucidated. This is the first demonstration of an agonist-regulated formation of a GPCR heterodimer of receptors expressed in platelets that results in a specific signaling consequence. Since we have previously shown that arrestin contributes to Akt activation, which in turn stabilizes platelet thrombi, we propose that agonist-regulated PAR4-P2Y12 association is one mechanism by which PAR4 and P2Y12 synergize to stabilize platelet-rich thrombi. We will test this hypothesis in future studies. 
